BCG vaccination to Mycobacterium leprae infection in mice

H. Nomaguchi, Y. Fukutomi, S. Nagai, Y. Yogi, H. Okamura, Naoya Oohara, M Matsuoka M, K. Nagata, T. Yamada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BCG vaccine (Tokyo strain) was given in BALB/cA mice intradermally 1 or 3 months before Mycobacterium leprae (M. leprae) challenge as modified Shepard's method. The vaccine dosage was 107-8 or 106. The BCG gave good protection in both dosages and both challenges against M. leprae infection. Lymphocytes proliferations of BCG-vaccinated splenocyte cultures in response to M. leprae lysate or BCG components (hsp65, 38kD, 30kD or 12kD protein) were tested, and potent proliferative responses were seen in the cultures with M. leprae lysate and hsp65. Furthermore, γ-IFN productions were positive in the cultures with M. leprae lysate or hsp65, but negative with other antigens. The production of γ-IFN with hsp65 was never inhibited with polymyxin B, but inhibited with IL 10. These results show that BCG (Tokyo strain) is a useful vaccine for M. leprae infection in mice, and one of the compounds of BCG, hsp65, may be a effective antigen component for protection of M. leprae infection inducing Th1 type cytokine.

Original languageEnglish
Pages (from-to)106-112
Number of pages7
JournalJapanese Journal of Leprosy
Volume65
Issue number2
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Mycobacterium leprae
Mycobacterium Infections
Mycobacterium bovis
Vaccination
Tokyo
Vaccines
BCG Vaccine
Antigens
Polymyxin B
Interleukin-10
Lymphocytes
Cytokines

Keywords

  • BCG
  • Cellular immunity
  • component
  • M. leprae
  • M. leprae
  • vaccine

ASJC Scopus subject areas

  • Dermatology

Cite this

Nomaguchi, H., Fukutomi, Y., Nagai, S., Yogi, Y., Okamura, H., Oohara, N., ... Yamada, T. (1996). BCG vaccination to Mycobacterium leprae infection in mice. Japanese Journal of Leprosy, 65(2), 106-112.

BCG vaccination to Mycobacterium leprae infection in mice. / Nomaguchi, H.; Fukutomi, Y.; Nagai, S.; Yogi, Y.; Okamura, H.; Oohara, Naoya; Matsuoka M, M; Nagata, K.; Yamada, T.

In: Japanese Journal of Leprosy, Vol. 65, No. 2, 1996, p. 106-112.

Research output: Contribution to journalArticle

Nomaguchi, H, Fukutomi, Y, Nagai, S, Yogi, Y, Okamura, H, Oohara, N, Matsuoka M, M, Nagata, K & Yamada, T 1996, 'BCG vaccination to Mycobacterium leprae infection in mice', Japanese Journal of Leprosy, vol. 65, no. 2, pp. 106-112.
Nomaguchi H, Fukutomi Y, Nagai S, Yogi Y, Okamura H, Oohara N et al. BCG vaccination to Mycobacterium leprae infection in mice. Japanese Journal of Leprosy. 1996;65(2):106-112.
Nomaguchi, H. ; Fukutomi, Y. ; Nagai, S. ; Yogi, Y. ; Okamura, H. ; Oohara, Naoya ; Matsuoka M, M ; Nagata, K. ; Yamada, T. / BCG vaccination to Mycobacterium leprae infection in mice. In: Japanese Journal of Leprosy. 1996 ; Vol. 65, No. 2. pp. 106-112.
@article{6d543a6610dc47b9b94bbeb99d20c8b6,
title = "BCG vaccination to Mycobacterium leprae infection in mice",
abstract = "BCG vaccine (Tokyo strain) was given in BALB/cA mice intradermally 1 or 3 months before Mycobacterium leprae (M. leprae) challenge as modified Shepard's method. The vaccine dosage was 107-8 or 106. The BCG gave good protection in both dosages and both challenges against M. leprae infection. Lymphocytes proliferations of BCG-vaccinated splenocyte cultures in response to M. leprae lysate or BCG components (hsp65, 38kD, 30kD or 12kD protein) were tested, and potent proliferative responses were seen in the cultures with M. leprae lysate and hsp65. Furthermore, γ-IFN productions were positive in the cultures with M. leprae lysate or hsp65, but negative with other antigens. The production of γ-IFN with hsp65 was never inhibited with polymyxin B, but inhibited with IL 10. These results show that BCG (Tokyo strain) is a useful vaccine for M. leprae infection in mice, and one of the compounds of BCG, hsp65, may be a effective antigen component for protection of M. leprae infection inducing Th1 type cytokine.",
keywords = "BCG, Cellular immunity, component, M. leprae, M. leprae, vaccine",
author = "H. Nomaguchi and Y. Fukutomi and S. Nagai and Y. Yogi and H. Okamura and Naoya Oohara and {Matsuoka M}, M and K. Nagata and T. Yamada",
year = "1996",
language = "English",
volume = "65",
pages = "106--112",
journal = "Japanese Journal of Leprosy",
issn = "1342-3681",
publisher = "Japanese Leprosy Association",
number = "2",

}

TY - JOUR

T1 - BCG vaccination to Mycobacterium leprae infection in mice

AU - Nomaguchi, H.

AU - Fukutomi, Y.

AU - Nagai, S.

AU - Yogi, Y.

AU - Okamura, H.

AU - Oohara, Naoya

AU - Matsuoka M, M

AU - Nagata, K.

AU - Yamada, T.

PY - 1996

Y1 - 1996

N2 - BCG vaccine (Tokyo strain) was given in BALB/cA mice intradermally 1 or 3 months before Mycobacterium leprae (M. leprae) challenge as modified Shepard's method. The vaccine dosage was 107-8 or 106. The BCG gave good protection in both dosages and both challenges against M. leprae infection. Lymphocytes proliferations of BCG-vaccinated splenocyte cultures in response to M. leprae lysate or BCG components (hsp65, 38kD, 30kD or 12kD protein) were tested, and potent proliferative responses were seen in the cultures with M. leprae lysate and hsp65. Furthermore, γ-IFN productions were positive in the cultures with M. leprae lysate or hsp65, but negative with other antigens. The production of γ-IFN with hsp65 was never inhibited with polymyxin B, but inhibited with IL 10. These results show that BCG (Tokyo strain) is a useful vaccine for M. leprae infection in mice, and one of the compounds of BCG, hsp65, may be a effective antigen component for protection of M. leprae infection inducing Th1 type cytokine.

AB - BCG vaccine (Tokyo strain) was given in BALB/cA mice intradermally 1 or 3 months before Mycobacterium leprae (M. leprae) challenge as modified Shepard's method. The vaccine dosage was 107-8 or 106. The BCG gave good protection in both dosages and both challenges against M. leprae infection. Lymphocytes proliferations of BCG-vaccinated splenocyte cultures in response to M. leprae lysate or BCG components (hsp65, 38kD, 30kD or 12kD protein) were tested, and potent proliferative responses were seen in the cultures with M. leprae lysate and hsp65. Furthermore, γ-IFN productions were positive in the cultures with M. leprae lysate or hsp65, but negative with other antigens. The production of γ-IFN with hsp65 was never inhibited with polymyxin B, but inhibited with IL 10. These results show that BCG (Tokyo strain) is a useful vaccine for M. leprae infection in mice, and one of the compounds of BCG, hsp65, may be a effective antigen component for protection of M. leprae infection inducing Th1 type cytokine.

KW - BCG

KW - Cellular immunity

KW - component

KW - M. leprae

KW - M. leprae

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=0029820597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029820597&partnerID=8YFLogxK

M3 - Article

C2 - 8810563

AN - SCOPUS:0029820597

VL - 65

SP - 106

EP - 112

JO - Japanese Journal of Leprosy

JF - Japanese Journal of Leprosy

SN - 1342-3681

IS - 2

ER -